Rank 28 • Biotech & Discovery
Insilico Medicine
Utilizes generative AI pipelines to discover targets and design novel molecules for clinical development.
Visit website- Signal Score
- 90
- Total raised
- $400M
- Stage
- Series D+
- Founded
- 2014
- Headquarters
- Hong Kong, China
- Region
- Asia-Pacific
Their signal
With multiple AI-designed drug candidates advancing through active human clinical trials, Insilico Medicine consistently demonstrates the practical translation of generative artificial intelligence from theory into validated biological therapies.
Signal Score 90editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in Biotech & Discovery
Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.